This quick-read pulls from my “Medical Device 101” presentation, a session packed with field-tested guidance for first-time and veteran teams alike. It’s designed to help you follow the webinar with a checklist in hand and turn those notes into action.
Watch the full video here:https://www.youtube.com/watch?v=EnjRMOB1Uio
Getting an FDA submission across the finish line isn’t exactly a walk in the park—unless that park features an obstacle course of red tape and acronyms. But take heart, because it’s time to turn vague “regulatory” concepts into a concrete sequence you can execute.
Here are 10 smart moves that’ll keep you on track (and out of regulatory purgatory) with timestamps to the relevant portion of the video:
#1 — Start with what FDA means by “risk” (02:41)
Understanding FDA’s risk model is the foundation of any submission strategy. About 45–50% of devices fall into Class I, 40–45% into Class II, and 5–10% into Class III, with a small unclassified category. Risk level dictates the controls: all devices face general controls, many Class II devices require additional special controls, and high-risk Class III devices must go through PMA. Think of it as a spectrum—bandages and exam gloves on the low-risk end, infusion pumps and powered wheelchairs in the middle, and heart valves and implants at the top.
Key takeaway: The name on your label matters less than the control set you’ll be living with. To make this actionable, draft a one-page “risk thesis” that clearly states your device’s class, the applicable controls, and your rationale.
#2 — Lock your intended use first, then build everything around it (09:27–10:32)
Locking down your intended use is the backbone of a strong FDA strategy. Intended use serves as the umbrella, with indications—population, duration, anatomy—acting as the spokes, and even a single word change can ripple through testing requirements, timelines, and costs.
Key takeaway: The earlier you finalize this language, the smoother your downstream path will be. To keep everyone aligned, create one approved paragraph for Intended Use and a version-controlled bulleted list of Indications.
#3 — Let language decide if you’re a medical device (13:15 – 15:29)
Whether a product qualifies as a medical device often comes down to language. A desk lamp is just a lamp—until you claim it “combats depression.” Any statement that suggests diagnosing, treating, mitigating, or preventing disease (without acting as a drug) moves the product into device territory. This is where teams frequently stumble, as marketing language tends to get ahead of regulatory boundaries.
Key takeaway: To stay on track, run every claim through a simple “device or not?” checklist before it appears in decks, on websites, or on packaging.
For more on medical device claims, check out our You Can’t Say That! Masterclass: https://youtu.be/TAzdwZ6n_LE
#4 — Remember the diaper test (16:04 – 17:57)
When it comes to FDA classification, context matters more than materials. For example, infant diapers aren’t devices, but adult diapers are because they address incontinence—a medical condition. The form may look the same, but the intent changes the rules. When stakeholders argue “it’s just…” remind them that intent determines whether a product is simply a product or a regulated device.
Key Takeaway: Create a two-column table showing product context versus regulatory outcome to help your team internalize this distinction.
Following the right database sequence can save months of work. Start in the Product Classification database to identify your product code, then trace it through the CFR regulation text and the recognized consensus standards. The nuances matter—a “surgical mask” can fall into five different regulatory categories depending on claims such as comfort, surgical, antimicrobial, pediatric, or N95/NIOSH. Standards drive testing, and testing, in turn, defines your minimum design specifications.
Key Takeaway: Capture screenshots of your product code, regulation text, and standards, and staple them into your DHF as your “Regulatory Ground Truth.”
Sequencing your regulatory steps in the right order reduces surprises and rework. The path is straightforward: define the product, confirm it qualifies as a device, determine its class and pathway, build valid scientific evidence, and finally, file the premarket submission. Valid evidence can include bench, sterilization, biocompatibility, performance, and usability testing—and when risk demands it, animal or clinical studies. Think of each step as the acceptance criteria for moving on to the next.
Key Takeaway: Build a single-page Gantt chart that maps these five steps to specific tests, owners, and artifacts to keep the process clear and on track.
A successful 510(k) submission comes down to telling one clear, consistent comparison story. Substantial equivalence requires the same intended use and the same technology—or differences that don’t raise new safety or effectiveness questions. If only one feature differs, cite a single reference predicate for that feature; pile on too many and your submission risks becoming a “Frankenstein” that gets steered toward the de novo pathway instead.
Key Takeaway: Draft a one-page Substantial Equivalence (SE) matrix that outlines intended use, technological characteristics, tests, differences, and rationale.
#8 — Respect the clocks, the pages, and the fees (43:32–45:59)
Time and cost are dictated by your regulatory pathway. A 510(k) typically runs about 90 FDA-clock days (~200 to decision), de novo averages 120 clock days (~400 real), and PMA takes roughly 180 clock days (~800 real), often with a pre-approval inspection. Fees scale with complexity—from thousands for 510(k), to tens of thousands for de novo, to six figures for PMA. Page counts follow the same trend: hundreds to low thousands for 510(k), several thousand for de novo, and binder upon binder for PMA.
Key Takeaway: Include review timelines, budget ranges, and submission size in your executive brief so everyone aligns on the same runway.
Bringing regulatory strategy in early saves time, money, and headaches. The best moment to align is between ideation and market validation, when you can define testing strategies and budgets before building your first prototype. Early design controls ensure you generate testable specifications, create production-equivalent units for submission testing, and establish a full QMS before your first commercial lot.
Key Takeaway: Stand up minimal design controls now—design plan, inputs/outputs, reviews, verification, validation, and a DHF—to avoid costly rebuilds later.
Four words anchor every regulatory decision: claims, codes, controls, and evidence. Claims define the product codes, codes trigger the applicable controls, and controls determine the level of evidence required. Using this framework to guide questions, track status, and assess risk transforms submissions from mysteries into manageable projects.
Key Takeaway: Kick off your next team stand-up by asking, “What changed in our claims, codes, controls, or evidence this week?” to keep everyone aligned.
Regulatory submissions don’t have to feel overwhelming when you break them down into a structured sequence. By understanding how FDA defines risk, locking in your intended use early, and keeping language aligned with regulatory boundaries, you set a strong foundation. From there, context, claims, codes, and controls guide your path forward—while smart database use, thoughtful sequencing, and a clean 510(k) comparison story keep you efficient and focused. Layer in realistic expectations around timelines, budgets, and submission size, and bring regulatory strategy in early so you’re building on solid ground rather than backtracking later. At the end of the day, success comes from discipline: a team that regularly checks its claims, codes, controls, and evidence is a team that transforms FDA submissions from stressful mysteries into predictable projects.
If this topic is relevant to what you’re working on, a few additional resources you might find useful:
-
A bit more depth: FDA Regulatory Pathways Explained: 510(k), de novo, PMA, Pre-Subs & eSTAR
-
Quick walkthrough: Don’t Ignore Your FDA Submission Strategy
-
Another video option: Inside the FDA: Pre-Subs, Wellness Devices & the Rise of “Inherent Use
Pick whichever format fits your attention span that day.
